Get the Stockscreener App
3.04
7.60%
-0.25
Pre-market:
3.07
0.03
+0.99%
Ironwood Pharmaceuticals Inc stock is traded at $3.04, with a volume of 1.69M.
It is down -7.60% in the last 24 hours and down -19.79% over the past month.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
See More
Previous Close:
$3.29
Open:
$3.26
24h Volume:
1.69M
Relative Volume:
0.37
Market Cap:
$495.70M
Revenue:
$296.15M
Net Income/Loss:
$24.02M
P/E Ratio:
25.21
EPS:
0.1206
Net Cash Flow:
$127.01M
1W Performance:
-6.46%
1M Performance:
-19.79%
6M Performance:
+121.90%
1Y Performance:
+104.03%
1-Day Range:
$3.035
$3.26
1-Week Range:
$3.015
$3.40
52-Week Range:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.04 | 495.70M | 296.15M | 24.02M | 127.01M | 0.1206 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9%Time to Buy? - MarketBeat
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Will Linzess continue to aid IRWD's top line in 2026 after a soft Q4? - MSN
Market Pulse: Is Ironwood Pharmaceuticals Inc forming a breakout patternCEO Change & Scalable Portfolio Growth Methods - baoquankhu1.vn
Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD) - The Globe and Mail
IRWD Stock Price, Quote & Chart | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8% - Stock Titan
Aug Rallies: Is Ironwood Pharmaceuticals Inc affected by consumer sentiment2026 Trade Ideas & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Pullback Watch: How much upside does Ironwood Pharmaceuticals Inc have2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
Insider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells 6,730,800 Shares of Stock - MarketBeat
Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals director Denner sells $20.5m in shares - Investing.com
Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale - Stock Titan
Breakouts Watch: Is Ironwood Pharmaceuticals Incs growth already priced in2026 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 15.8% in February - MarketBeat
Trade Report: Can Ironwood Pharmaceuticals Inc outperform in the next rallyWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant - Stock Titan
Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award - Stock Titan
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant - Stock Titan
Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award - Stock Titan
Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award - Stock Titan
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Ironwood Pharma Maintains Revolving Credit Facility to 2028 - The Globe and Mail
Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing - Minichart
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity - Investing.com
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10 - TradingView
Ironwood Pharmaceuticals, Inc. Notifies Wells Fargo Bank, National Association of Satisfaction of Liquidity Conditions Under Amended Credit Agreement - marketscreener.com
Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028 - Stock Titan
Investment Review: Can Ironwood Pharmaceuticals Inc stock double in the next yearJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Aug Reactions: Will Ironwood Pharmaceuticals Inc outperform the market in YEAR2025 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? - Yahoo Finance
Ironwood Pharma Stock Quote, Share Price, News and Analysis - Longbridge
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - PharmiWeb.com
US Stocks Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSJuly 2025 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Report: Can Ironwood Pharmaceuticals Inc stock double in the next yearPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
IRWD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IRWD Should I Buy - Intellectia AI
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 10.1%Time to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
Jefferies Maintains Hold on Ironwood Pharmaceuticals (IRWD) Feb 26, 2026 - Meyka
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha
Jefferies raises Ironwood Pharmaceuticals stock price target on Linzess outlook - Investing.com Canada
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):